Moderna RSV Vaccine Approved: Ages 18-59
- Moderna's RSV vaccine, mResvia, now has expanded FDA approval to include adults aged 18 to 59 who face an elevated risk of severe illness from respiratory syncytial virus.
- the FDA's decision marks a significant step in preventative care for vulnerable populations.
- An April vote by the CDC's Advisory Committee on Immunization Practices (ACIP) recommended RSV vaccines for adults aged 50 to 59 with specific medical conditions.
Moderna’s mResvia RSV vaccine gains expanded FDA approval, now including adults aged 18-59 at high risk, a significant advancement in protecting vulnerable populations from severe respiratory syncytial virus. This progress marks a crucial step forward; the mRNA vaccine platform proves its continued effectiveness. While the FDA approved the vaccine, CDC recommendations for the 50-59 age group face pending approval. The absence of this could impact insurance coverage. News Directory 3 reports on the potential impact of this expansion. Moderna anticipates mResvia availability for the 2025-2026 respiratory virus season. Discover what’s next for RSV prevention.
Moderna RSV Vaccine Approved for expanded Adult Use
Moderna’s RSV vaccine, mResvia, now has expanded FDA approval to include adults aged 18 to 59 who face an elevated risk of severe illness from respiratory syncytial virus. This broadens teh vaccine’s availability beyond the initial approval for those 60 and older.
the FDA’s decision marks a significant step in preventative care for vulnerable populations. The mRNA vaccine platform continues to be a key tool in combating respiratory illnesses.
The path forward isn’t entirely clear,however. An April vote by the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended RSV vaccines for adults aged 50 to 59 with specific medical conditions. this recommendation, intended to include any licensed RSV vaccine, now encompasses Moderna’s mResvia. However, final approval from the CDC director or the Health and Human Services secretary is pending.
Without this approval, insurers are not obligated to cover the cost of the vaccine for individuals in this age group. The situation is further elaborate by recent changes to the ACIP.
Moderna faced another setback recently when the HHS canceled grants for mRNA flu vaccine progress, citing unsubstantiated safety concerns.
“RSV poses a serious health risk to adults with certain chronic conditions, and today’s approval marks an crucial step forward in our ability to protect additional populations from severe illness from RSV,” Moderna CEO stéphane Bancel said.
What’s next
Moderna anticipates mRESVIA availability for both the newly approved younger adult group and those 60 and older in time for the 2025-2026 respiratory virus season. The expanded approval offers a new tool in the ongoing effort to combat RSV and protect vulnerable individuals.